| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| CDMO收入(元) | 34,347,269.81 | 44,112,429.36 | 11,641,818.36 | 41,722,766.77 | 5,120,501.42 |
| 临床服务(元) | 25,025,387.69 | 136,173,817.38 | 81,435,255.48 | 213,087,501.34 | 92,585,687.43 |
| 临床前药学研究(元) | 34,157,663.03 | 121,894,739.56 | 78,309,150.24 | 193,540,352.90 | 154,323,246.34 |
| 权益分成(元) | 3,218,882.80 | 6,238,404.32 | 4,450,807.72 | 8,495,795.57 | 4,554,144.77 |
| 商业化生产(元) | 59,854,346.47 | 89,280,923.80 | 34,150,011.34 | 36,694,012.57 | 2,518,324.69 |
| 自主研发技术成果转化(元) | 143,118,881.24 | 247,305,950.27 | 106,987,278.89 | 287,770,388.50 | 248,802,477.52 |
| 其他(元) | 4,719,670.57 | 32,980,829.99 | 15,378,790.75 | 20,612,426.57 | 17,157,152.95 |
| 营业成本(元) | |||||
| CDMO收入(元) | 16,347,837.73 | 23,437,287.95 | 7,061,361.21 | 23,100,857.40 | 2,231,238.69 |
| 临床服务(元) | 22,227,945.37 | 97,569,909.83 | 41,853,979.41 | 132,453,385.43 | 57,979,307.95 |
| 临床前药学研究(元) | 31,101,697.00 | 73,125,644.11 | 35,045,367.21 | 85,692,372.81 | 48,417,655.20 |
| 权益分成(元) | - | - | - | - | - |
| 商业化生产(元) | 64,211,473.19 | 117,502,510.66 | 44,771,329.47 | 51,704,733.66 | 5,853,041.07 |
| 自主研发技术成果转化(元) | 20,502,013.67 | 85,226,023.80 | 26,973,345.49 | 76,846,872.44 | 36,292,616.44 |
| 其他(元) | 6,567,881.66 | 13,299,771.33 | 8,029,721.99 | 15,266,191.93 | 13,295,636.02 |
| 毛利(元) | |||||
| CDMO收入(元) | 17,999,432.08 | 20,675,141.41 | 4,580,457.15 | 18,621,909.37 | 2,889,262.73 |
| 临床服务(元) | 2,797,442.32 | 38,603,907.55 | 39,581,276.07 | 80,634,115.91 | 34,606,379.48 |
| 临床前药学研究(元) | 3,055,966.03 | 48,769,095.45 | 43,263,783.03 | 107,847,980.09 | 105,905,591.14 |
| 权益分成(元) | 3,218,882.80 | 6,238,404.32 | 4,450,807.72 | 8,495,795.57 | 4,554,144.77 |
| 商业化生产(元) | -4,357,126.72 | -28,221,586.86 | -10,621,318.13 | -15,010,721.09 | -3,334,716.38 |
| 自主研发技术成果转化(元) | 122,616,867.57 | 162,079,926.47 | 80,013,933.40 | 210,923,516.06 | 212,509,861.08 |
| 其他(元) | -1,848,211.09 | 19,681,058.66 | 7,349,068.76 | 5,346,234.64 | 3,861,516.93 |
| 毛利率(%) | |||||
| CDMO收入(%) | 52.40 | 46.87 | 39.34 | 44.63 | 56.43 |
| 临床服务(%) | 11.18 | 28.35 | 48.60 | 37.84 | 37.38 |
| 临床前药学研究(%) | 8.95 | 40.01 | 55.25 | 55.72 | 68.63 |
| 权益分成(%) | - | - | - | - | - |
| 商业化生产(%) | -7.28 | -31.61 | -31.10 | -40.91 | -132.42 |
| 自主研发技术成果转化(%) | 85.67 | 65.54 | 74.79 | 73.30 | 85.41 |
| 其他(%) | -39.16 | 59.67 | 47.79 | 25.94 | 22.51 |
| 收入构成(%) | |||||
| CDMO收入(%) | 11.28 | 6.51 | 3.50 | 5.20 | 0.98 |
| 临床服务(%) | 8.22 | 20.09 | 24.50 | 26.57 | 17.63 |
| 临床前药学研究(%) | 11.22 | 17.98 | 23.56 | 24.13 | 29.39 |
| 权益分成(%) | 1.06 | 0.92 | 1.34 | 1.06 | 0.87 |
| 商业化生产(%) | 19.66 | 13.17 | 10.28 | 4.58 | 0.48 |
| 自主研发技术成果转化(%) | 47.01 | 36.48 | 32.19 | 35.89 | 47.39 |
| 其他(%) | 1.55 | 4.86 | 4.63 | 2.57 | 3.27 |
| 毛利构成(%) | |||||
| CDMO收入(%) | 12.54 | 7.72 | 2.72 | 4.47 | 0.80 |
| 临床服务(%) | 1.95 | 14.41 | 23.47 | 19.34 | 9.59 |
| 临床前药学研究(%) | 2.13 | 18.21 | 25.66 | 25.87 | 29.34 |
| 权益分成(%) | 2.24 | 2.33 | 2.64 | 2.04 | 1.26 |
| 商业化生产(%) | -3.04 | -10.54 | -6.30 | -3.60 | -0.92 |
| 自主研发技术成果转化(%) | 85.46 | 60.52 | 47.45 | 50.60 | 58.87 |
| 其他(%) | -1.29 | 7.35 | 4.36 | 1.28 | 1.07 |